scholarly journals Statin-ezetimibe versus statin lipid-lowering therapy in patients with acute coronary syndromes undergoing percutaneous coronary intervention

2017 ◽  
Vol 9 (5) ◽  
pp. 1345-1352 ◽  
Author(s):  
Yun-Yan Dai ◽  
Hai-Shan Zhang ◽  
Xin-Gang Zhang ◽  
Qi-Gang Guan ◽  
Yuan Gao ◽  
...  
Keyword(s):  
Percutaneous Coronary Intervention ◽  
Acute Coronary Syndromes ◽  
Coronary Intervention ◽  
Lipid Lowering ◽  
Lipid Lowering Therapy ◽  
Lowering Therapy ◽  
Percutaneous Coronary ◽  
Coronary Syndromes

Prevalence of Smoking and Adherence to Lipid-lowering Therapy in Patients Following Percutaneous Coronary Intervention

2008 ◽  
Vol 17 ◽  
pp. S111
Author(s):  
William Chan ◽  
Angela Brennan ◽  
Michelle J. Butler ◽  
Nick Andrianopoulos ◽  
David J. Clark ◽  
...  
Keyword(s):  
Percutaneous Coronary Intervention ◽  
Coronary Intervention ◽  
Lipid Lowering ◽  
Lipid Lowering Therapy ◽  
Lowering Therapy ◽  
Percutaneous Coronary

scholarly journals Achievement of European guideline-recommended lipid levels post-percutaneous coronary intervention: A population-level observational cohort study

2020 ◽  
pp. 204748732091411
Author(s):  
Daniel E Harris ◽  
Arron Lacey ◽  
Ashley Akbari ◽  
Fatemeh Torabi ◽  
Dave Smith ◽  
...  
Keyword(s):  
Percutaneous Coronary Intervention ◽  
European Society ◽  
Density Lipoprotein ◽  
Coronary Intervention ◽  
Lipid Lowering ◽  
Lipid Lowering Therapy ◽  
European Atherosclerosis Society ◽  
Lowering Therapy ◽  
Percutaneous Coronary ◽  
European Society Of Cardiology

Aims European Society of Cardiology/European Atherosclerosis Society 2019 guidelines recommend more aggressive lipid targets in high- and very high-risk patients and the addition of adjuvant treatments to statins in uncontrolled patients. We aimed to assess (a) achievement of prior and new European Society of Cardiology/European Atherosclerosis Society lipid targets and (b) lipid-lowering therapy prescribing in a nationwide cohort of very high-risk patients. Methods We conducted a retrospective observational population study using linked health data in patients undergoing percutaneous coronary intervention (2012–2017). Follow-up was for one-year post-discharge. Results Altogether, 10,071 patients had a documented LDL-C level, of whom 48% had low-density lipoprotein cholesterol (LDL-C)<1.8 mmol/l (2016 target) and (23%) <1.4 mmol/l (2019 target). Five thousand three hundred and forty patients had non-high-density lipoprotein cholesterol (non-HDL-C) documented with 57% <2.6 mmol/l (2016) and 37% <2.2 mmol/l (2019). In patients with recurrent vascular events, fewer than 6% of the patients achieved the 2019 LDL-C target of <1.0 mmol/l. A total of 10,592 patients had triglyceride (TG) levels documented, of whom 14% were ≥2.3 mmol/l and 41% ≥1.5 mmol/l (2019). High-intensity statins were prescribed in 56.4% of the cohort, only 3% were prescribed ezetimibe, fibrates or prescription-grade N-3 fatty acids. Prescribing of these agents was lower amongst patients above target LDL-C, non-HDL-C and triglyceride levels. Females were more likely to have LDL-C, non-HDL-C and triglyceride levels above target. Conclusion There was a low rate of achievement of the new European Society of Cardiology/European Atherosclerosis Society lipid targets in this large post-percutaneous coronary intervention population and relatively low rates of intensive lipid-lowering therapy prescribing in those with uncontrolled lipids. There is considerable potential to optimise lipid-lowering therapy further through statin intensification and appropriate use of novel lipid-lowering therapy, especially in women.

Insufficient lipid lowering therapy could not bring favorable prognostic effect in high risk patients who were functionally deferred percutaneous coronary intervention

2020 ◽  
Vol 41 (Supplement_2) ◽  
Author(s):  
T Abe ◽  
K Jujo ◽  
T Moriyama ◽  
Y Iwanami ◽  
K Shimazaki ◽  
...  
Keyword(s):  
Percutaneous Coronary Intervention ◽  
Primary Endpoint ◽  
Coronary Stenosis ◽  
Coronary Intervention ◽  
Lipid Lowering ◽  
Lipid Lowering Therapy ◽  
Close Monitoring ◽  
Fractional Flow ◽  
Lowering Therapy ◽  
Percutaneous Coronary

Abstract Introduction Deferral of percutaneous coronary intervention (PCI) of a functionally insignificant stenosis is associated with favorable long-term prognoses. However, previous reports revealed that patients with fractional flow reserve (FFR) 0.81–0.85 had higher cardiovascular adverse event rates than those with FFR &gt;0.85. Numbers of large clinical trials established the lower, the better strategy for low-density lipoprotein cholesterol (LDL-C) management for patients after PCI. However, in the real clinical practice, the achievement rate of target LDL-C is often insufficient in patients with atherosclerotic risk factors who were functionally deferred PCI. Purpose We aimed to examine optimal LDL-C management for patients with intermediate coronary stenosis deferred PCI by FFR measurement. Methods This observational study included 293 consecutive patients with coronary stenosis deferred PCI due to greater FFR than 0.80. We separately analyzed 90 patients with 0.81–0.85 of FFR and 203 patients with &gt;0.85. Patients in each group were further classified into 2 groups based on LDL-C level at one year after FFR measurement; the Lower LDL-C group (&lt;100 mg/dL) and the Higher LDL-C group (&gt;100 mg/dL). The primary endpoint was major adverse cardiovascular and cerebrovascular events (MACCE) including death, non-fatal myocardial infarction, ischemic stroke, heart failure hospitalization and unplanned revascularization. Results Patients with FFR 0.81–0.85 had a significantly higher MACCE rate than those with FFR &gt;0.85 (hazard ratio (HR): 1.77, 95% confidence interval (CI): 1.02–3.07, p=0.043). In patients with FFR 0.81–0.85, the Lower LDL-C group (n-=53) had a significantly lower rate of the primary endpoint than the Higher LDL-C group (HR: 0.41, 95% CI: 0.18–0.97, Log-rank p=0.036, Figure A). Whereas, there was no significant difference in the event rate between 2 groups in patients with FFR &gt;0.85 (Log-rank p=0.42, Figure B). Conclusion Uncontrolled LDL-C level was associated with higher MACCE rate in patients who were deferred PCI due to FFR 0.81–0.85. These results suggested that even in patients who were deferred PCI, those with coronary artery stenosis of lower FFR value should receive strict LDL-C lowering therapy with close monitoring. Figure 1 Funding Acknowledgement Type of funding source: None

Sign in / Sign up

Export Citation Format

Share Document